Investors
FAQ
What is AXIM Biotechnologies, Inc.'s stock symbol?
Our stock is traded on the OTCQB under the symbol AXIM.
How can I buy AXIM shares?
You can buy AXIM shares through a broker, just as you would other securities.
How can I keep up to date with latest developments at AXIM?
You can register to receive updates announced by AXIM by submitting your email address in Email Alerts on the Investor Relations section of our website.
When was AXIM Biotechnologies, Inc. incorporated?
2010
When did AXIM Biotechnologies, Inc. become a public company?
March 2014
Where is AXIM Biotechnologies, Inc. located?
6191 Cornerstone Court, E., Suite 114,
San Diego, CA 92121
When is AXIM Biotechnologies, Inc.'s fiscal year end?
December 31st
Who is AXIM Biotechnologies, Inc.'s transfer agent?
Action Stock Transfer Corporation
2469 E. Fort Union Blvd
Suite 214
Salt Lake City, UT 84121
T: 801-274-1088
info@actionstocktransfer.com
www.actionstocktransfer.com
Who is AXIM Biotechnologies, Inc.'s independent auditor?
RBSM LLP
805 Third Avenue
Suite 902
New York, NY 10022
T: 212-868-3669
www.rbsmllp.com
Who is AXIM Biotechnologies, Inc.'s outside legal counsel?
Phillip E. Koehnke, APC
PO Box 235472
Encinitas, CA 92024
T: 858-229-8116
pek@peklaw.com
Email Alerts
Stay informed and receive company updates straight to your inbox
Recent News
AXIM Biotechnologies Completes Optimization of Only FDA-Cleared IgE Rapid Diagnostics Test – In-House Manufacturing Lowers Cost and Eliminates Supply Chain Expenditures
SAN DIEGO, May 24, 2022 (GLOBE NEWSWIRE) -- AXIM Biotechnologies, Inc (OTCQB: AXIM) (“AXIM Biotech,” “AXIM” or “the Company”), an international healthcare solutions company targeting ocular surface diseases announced today that its scientific team has completed the...
AXIM Biotechnologies Develops Novel Tear Sample Collector System, Files Patent Application
SAN DIEGO, May 10, 2022 (GLOBE NEWSWIRE) -- AXIM Biotechnologies, Inc (OTCQB: AXIM) (“AXIM Biotech,” “AXIM” or “the Company”), an international healthcare solutions company targeting dry eye disease (DED), today announced that it has developed a novel tear sample...
AXIM Develops Quantitative Rapid Diagnostic Test for Lacritin; Now Boasts Four Dry Eye Disease Point-of-Care Biomarker Tests
SAN DIEGO, April 27, 2022 (GLOBE NEWSWIRE) -- AXIM® Biotechnologies, Inc. (OTCQB: AXIM) (“AXIM® Biotech,” “AXIM” or “the Company”), an international healthcare solutions company targeting Dry Eye Disease (DED), announced today that it has successfully developed a...
